Drug Trial Radar · NCT05593328
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation
Last checked: Nov 19, 2026Latest source record: Jan 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
23
Actual
Start
Mar 17, 2023
Primary completion
Dec 9, 2024
Study completion Dec 9, 2024
Sponsor
- Lead sponsor
- Cardiff OncologyIndustry
- Sponsor type
- Industry
- First posted
- Oct 25, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to assess the efficacy of 2 different doses of onvansertib in combination with a chemotherapy regimen of irinotecan, fluorouracil \[5-FU\], and leucovorin (FOLFIRI) and bevacizumab for treatment of confirmed metastatic and/or unresectable colorectal cancer (CRC) in participants with a kirsten rat sarcoma virus gene (KRAS) or neuroblastoma-RAS (NRAS) mutation who have progressed on an oxaliplatin/fluoropyrimidinebased regimen in the first-line setting.
Conditions
- Colorectal Cancer
- Metastatic Colorectal Cancer
Interventions
OnvansertibDrug
Oral capsule
FOLFIRIDrug
FOLFIRI (irinotecan + fluorouracil \[5-FU\] + leucovorin) as intravenous (IV) infusion
BevacizumabDrug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response RateTime frame: Up to approximately 1 year
Locations
27 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic in Arizona - Phoenix Campus
Phoenix, Arizona
Central Arkansas Radiation Therapy Institute - Cancer Center
Little Rock, Arkansas
Pacific Cancer Medical Center
Anaheim, California
Comprehensive Blood and Cancer Center - Bakersfield
Bakersfield, California
Cancer and Blood Specialty Clinic
Los Alamitos, California
Norris Comprehensive Cancer Center
Los Angeles, California
UCI Health - Chao Family Comprehensive Cancer Center
Orange, California
UCLA Health - Santa Monica Parkside Cancer Care
Santa Monica, California
Torrance Memorial Physician Network - Cancer Care and Infusion Center
Torrance, California
PIH Health
Whittier, California
Mayo Clinic - Jacksonville
Jacksonville, Florida
Memorial Hospital West
Pembroke Pines, Florida
Cancer & Hematology Centers of Western Michigan - Lemmen-Holton Cancer Pavilion
Grand Rapids, Michigan
Mayo Clinic - Rochester
Rochester, Minnesota
Washington University School of Medicine Center for Advanced Medicine
St Louis, Missouri
Nebraska Cancer Specialists - Midwest Cancer Center - Legacy
Omaha, Nebraska
Englewood Health
Englewood, New Jersey
San Juan Oncology Associates
Farmington, New Mexico
Manhattan Hematology Oncology Associates
New York, New York
Gabrail Cancer and Research Center
Canton, Ohio
Trihealth Kenwood
Cincinnati, Ohio
University Hospitals Cleveland Medical Center
Cleveland, Ohio
West Cancer Center - East Campus
Germantown, Tennessee
University of Texas MD Anderson Cancer Center
Houston, Texas
Utah Cancer Specialists
Salt Lake City, Utah
University of Virginia School of Medicine
Charlottesville, Virginia
Inova Schar Cancer Institute
Fairfax, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.